New hope for leukemia patients: drug combo shows promise in early trial
NCT ID NCT04742101
First seen May 24, 2026 · Last updated Jun 19, 2026 · Updated 2 times
Summary
This study tested a new drug called S65487, which blocks a protein that helps cancer cells survive, combined with a standard drug azacitidine. The trial included 57 adults with untreated acute myeloid leukemia who were not healthy enough for intensive chemotherapy. The goal was to see if the combination is safe and can lead to complete remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
C. Universidad de Navarra Servicio de Hematologia
Pamplona, 31008, Spain
-
H. Universitario La Fe Servicio de Hematologia
Valencia, 46026, Spain
-
Hospital 12 de Octubre Servicio de Hematología
Madrid, 28041, Spain
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie Klinika Transplantacji Szpiku i Onkohematologii pokoj 4.041 ul. Wybrzeze Armii Krajowej 15
Gliwice, 44-102, Poland
-
Samsung Medical Center - Division of Hematology-Oncology
Seoul, 06351, South Korea
-
Semmelweis Egyetem Belgyógyászati és Onkológiai Klinika Klinikai Farmakológiai Részleg
Budapest, H-1083, Hungary
-
Seoul National University Hospital - Department of Hematology-Oncology
Seoul, 03080, South Korea
-
The Christie NHS foundation Trust
Manchester, M20 4BX, United Kingdom
-
University College London - Hospitals NHS Foundation Trust
London, NW1 2PG, United Kingdom
-
Western General Hospital
Edinburgh, EH4 2XU, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
S65487 (a Bcl2 inhibitor) and azacitidine
What this could lead to
If successful, this combination could offer a new treatment option for older or frail adults with acute myeloid leukemia who cannot tolerate intensive chemotherapy.
What could go wrong
This is an early-phase trial with only 57 participants, so results may not apply to all patients. The drug combination may cause side effects or fail to improve remission rates.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.